151 related articles for article (PubMed ID: 6976833)
1. 2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia.
Gray DP; Grever MR; Siaw MF; Coleman MS; Balcerzak SP
Cancer Treat Rep; 1982 Feb; 66(2):253-7. PubMed ID: 6976833
[TBL] [Abstract][Full Text] [Related]
2. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin.
Agarwal RP; Blatt J; Miser J; Sallan S; Lipton JM; Reaman GH; Holcenberg J; Poplack DG
Cancer Res; 1982 Sep; 42(9):3884-6. PubMed ID: 6980706
[TBL] [Abstract][Full Text] [Related]
4. Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin (dcf) and 9-beta-D-arabinofuranosyladenine (ara-A).
Yu AL; Mendelsohn J; Matsumoto SS
Adv Exp Med Biol; 1986; 195 Pt A():491-6. PubMed ID: 3487920
[No Abstract] [Full Text] [Related]
5. Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.
Kuroki Y; Shimoyama M; Inaba S; Hirose M
Jpn J Cancer Res; 1989 May; 80(5):482-9. PubMed ID: 2502523
[TBL] [Abstract][Full Text] [Related]
6. Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine.
Plunkett W; Benjamin RS; Keating MJ; Freireich EJ
Cancer Res; 1982 May; 42(5):2092-6. PubMed ID: 6175407
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid levels of 2'-deoxycoformycin after systemic administration in monkeys.
Blatt J; Venner PM; Riccardi R; Cohen LF; Gangji D; Glazer RI; Poplack DG
J Natl Cancer Inst; 1982 Mar; 68(3):391-3. PubMed ID: 6977672
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture.
Cass CE; Tan TH; Selner M
Cancer Res; 1979 May; 39(5):1563-9. PubMed ID: 85484
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
Cass CE; Au-Yeung TH
Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095
[TBL] [Abstract][Full Text] [Related]
10. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
Poplack DG; Sallan SE; Rivera G; Holcenberg J; Murphy SB; Blatt J; Lipton JM; Venner P; Glaubiger DL; Ungerleider R; Johns D
Cancer Res; 1981 Sep; 41(9 Pt 1):3343-6. PubMed ID: 6973390
[TBL] [Abstract][Full Text] [Related]
12. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts.
Holland MJ
Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439
[TBL] [Abstract][Full Text] [Related]
13. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
Venner PM; Glazer RI; Blatt J; Sallan S; Rivera G; Holcenberg JS; Lipton J; Murphy SB; Poplack DG
Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
[TBL] [Abstract][Full Text] [Related]
14. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
Caron N; Lee SH; Kimball AP
Cancer Res; 1977 Sep; 37(9):3274-9. PubMed ID: 884674
[TBL] [Abstract][Full Text] [Related]
15. Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin.
Trotta PP; Tedde A; Ikehara S; Pahwa R; Good RA; Balis ME
Cancer Res; 1981 Jun; 41(6):2189-96. PubMed ID: 6972248
[TBL] [Abstract][Full Text] [Related]
16. The treatment of hairy cell leukemia (HCL) with pentostatin (2'-deoxycoformycin, dCF).
Spiers AS; Parekh SJ
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():173-5. PubMed ID: 2653498
[No Abstract] [Full Text] [Related]
17. Morphologic changes and immunohistochemical localization of adenosine deaminase in tissues of rats given injections of 2'-deoxycoformycin.
Checkik BE; Perets A; SenGupta S; Fernandes B
J Natl Cancer Inst; 1983 Nov; 71(5):999-1010. PubMed ID: 6358608
[TBL] [Abstract][Full Text] [Related]
18. Therapy with 9-beta-D-arabinofuranosyladenine (ARA-A) and 2'-deoxycoformycin increases the ARA-A content of ocular tissues.
O'Brien WJ
Curr Eye Res; 1986 Aug; 5(8):595-9. PubMed ID: 3489583
[TBL] [Abstract][Full Text] [Related]
19. Low-dose deoxycoformycin in lymphoid malignancy.
Grever MR; Leiby JM; Kraut EH; Wilson HE; Neidhart JA; Wall RL; Balcerzak SP
J Clin Oncol; 1985 Sep; 3(9):1196-201. PubMed ID: 2993534
[TBL] [Abstract][Full Text] [Related]
20. Deoxyadenosine antagonism of the antiviral activity of 9-beta-D-arabinofuranosyladenine and 9-beta-D-arabinofuranosylhypoxanthine.
Smith SH; Shipman C; Drach JC
Cancer Res; 1978 Jul; 38(7):1916-21. PubMed ID: 207416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
